**Table 1. Сomparative analysis of galectin-3 levels in the patients with ovarian tumors and in the healthy donors**

|  |  |  |  |
| --- | --- | --- | --- |
| **Groups** | **N** | **Galectin-3, ng/mL, Me (Q1; Q3)** | **p value\*** |
| Control | 20 | 8.02 (5.61; 10.83) | – |
| Benign ovarian tumors | 32 | 7.43 (5.24; 10.40) | > 0.999 |
| Borderline ovarian tumors | 22 | 7.22 (6.05; 12.27) | > 0.999 |
| Epithelial ovarian cancer | 116 | 10.35 (7.68; 14.48) | 0.021 |
| Non-epithelial ovarian cancer | 6 | 5.49 (4.78; 10.93) | > 0.999 |

The values are given as median (Me), upper and lower quartiles (Q١; Q٣)

\* The comparison with the control group

**Table 2. Association of serum soluble galectin-3 levels with clinical and morphological characteristics in epithelial ovarian cancer patients**

|  |  |  |
| --- | --- | --- |
| **Characteristics** | **Galectin-3, ng/mL, Me (Q1; Q3)** | **p value\*** |
| Age: |  |  |
| ≤ 57 years | 9.03 (7.48; 12.18) | 0.009 |
| > 57 years | 11.69 (8.44; 15.59) |  |
| Histological type of the tumor: |  |  |
| Serous | 9.64 (7.66; 14.71) | 0.358 |
| Mucinous | 12.01 (9.03; 16.89) |  |
| Endometriod | 9.86 (7.44; 12.71) |  |
| Clear cell | 13.18 (11.69; 15.58) |  |
| Stage: |  |  |
| I–II | 10.43 (7.27; 13.18) | 0.322 |
| III–IV | 10.27 (7.93; 15.19) |  |
| Tumor size (Т): |  |  |
| T1–T2 | 10.51 (7.23; 13.95) | 0.377 |
| T3–T4 | 10.22 (8.03; 14.91) |  |
| Regional metastasis (N): |  |  |
| N0 | 10.21 (7.75; 13.79) | 0.760 |
| N+ | 11.46 (6.71; 15.53) |  |
| Distant metastasis (M): |  |  |
| M0 | 10.21 (7.72; 13.79) | 0.386 |
| M+ | 11.98 (7.57; 16.49) |  |
| Differentiation grade: |  |  |
| Low | 11.04 (7.41; 13.91) | 0.942 |
| High | 10.27 (7.75; 14.78) |  |
| Ascitis (A): |  |  |
| А- | 11.12 (7.81; 13.48) | 0.733 |
| А+ | 10.35 (7.78; 15.42) |  |
| Location: |  |  |
| Unilateral | 11.26 (7.57; 14.97) | 0.798 |
| Bilateral | 9.59 (8.02; 13.65) |  |

The values are given as median (Me), upper and lower quartiles (Q١; Q٣)

\* Mann-Whitney and Kruskall-Wallis tests